Related Experiment Video
Updated: Jul 16, 2025

Murine Kidney Transplant Technique
Published on: October 20, 2015
Thrombotic microangiopathies after kidney transplantation in modern era: nosology based on chronology
Florent Von Tokarski1, Alexandre Fillon1, Valentin Maisons1
1Service de Néphrologie-HTA, Dialyses, Transplantation Rénale, Hôpital Bretonneau Et Hôpital Clôcheville, CHU Tours, 2 Bd Tonnellé, 37044, Tours, Tours Cedex, France.
Background:
Thrombotic microangiopathies (TMAs) are rare but can be severe in kidney transplant. recipients (KTR).
Methods:
We analysed the epidemiology of adjudicated TMA in consecutive KTR during the. 2009-2021 period.
Results:
TMA was found in 77/1644 (4.7%) KTR. Early TMA (n = 24/77 (31.2%); 1.5% of all KTR) occurred during the first two weeks ((median, IQR) 3 [1-8] days). Triggers included acute antibody-mediated rejection (ABMR, n = 4) and bacterial infections (n = 6). Graft survival (GS) was 100% and recurrence rate (RR) was 8%. Unexpected TMA (n = 31/77 (40.2%); 1.5/1000 patient-years) occurred anytime during follow-up (3.0 (0.5-6.2) years). Triggers included infections (EBV/CMV: n = 10; bacterial: n = 6) and chronic active ABMR (n = 5). GS was 81% and RR was 16%. Graft-failure associated TMA (n = 22/77 (28.6%); 2.2% of graft losses) occurred after 8.8 (4.9-15.5) years). Triggers included acute (n = 4) or chronic active (n = 14) ABMR, infections (viral: n = 6; bacterial: n = 5) and cancer (n = 6). 15 patients underwent transplantectomy. RR was 27%. Atypical (n = 6) and typical (n = 2) haemolytic and uremic syndrome, and isolated CNI toxicity (n = 4) were rare. Two-third of biopsies presented TMA features.
Conclusions:
TMA are mostly due to ABMR and infections; causes of TMA are frequently combined. Management often is heterogenous. Our nosology based on TMA timing identifies situations with distinct incidence, causes and prognosis.
Insights
Thrombotic microangiopathies (TMAs) in kidney transplant recipients are often linked to antibody-mediated rejection and infections. Understanding TMA timing is key to distinct prognoses and management strategies.
Area of Science:
- Nephrology
- Transplantation Immunology
- Pathology
Background:
- Thrombotic microangiopathies (TMAs) represent a rare but severe complication in kidney transplant recipients (KTR).
- TMAs can significantly impact graft survival and patient outcomes.
Purpose of the Study:
- To analyze the epidemiology of adjudicated TMAs in kidney transplant recipients.
- To identify the incidence, triggers, and outcomes associated with different TMA timings.
Main Methods:
- Analysis of adjudicated TMA cases in consecutive KTR from 2009-2021.
- Categorization of TMAs based on timing: early, unexpected, and graft-failure associated.
Main Results:
- TMA occurred in 4.7% of KTR, with early TMA (1.5%) linked to rejection or infection and 100% graft survival.
- Unexpected TMA (1.5/1000 patient-years) had varied triggers including infections and chronic active ABMR, with 81% graft survival.
- Graft-failure associated TMA (2.2% of graft losses) occurred later, often linked to chronic active ABMR, infections, or cancer, with a 27% recurrence rate.
Conclusions:
- TMAs in KTR are primarily driven by antibody-mediated rejection (ABMR) and infections, often with combined causes.
- A nosology based on TMA timing reveals distinct patterns in incidence, etiology, and prognosis.
- Heterogeneous management strategies highlight the need for tailored approaches based on TMA classification.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease I: Introduction
Kidney Transplant I: Introduction
Nephrotic Syndrome I : Introduction
Acute Kidney Injury II: Pathophysiology
Kidney Transplant III: Nursing Management

